Mural im La Mission District San Francisco (Aufnahme Oncoletter)
Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
Für eine vollständige Ansicht aller 20 Abstract-Titel nutzen Sie bitte die Desktop-Version von Oncoletter
Link to Abstracts
Link to Posters: Sie müssen bei ASCO-GI eingeloggt sein und über eine aktuelle Registrierung verfügen, um auf die Poster dieser Sitzung zugreifen zu können. Hier können Sie die Registrierung erwerben.
- Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.
- Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.
- A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).
- Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
- First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
- A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
- Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
- Surgeon fatigue in robot-assisted and laparoscopic gastrectomy for gastric cancer: Exploratory prospective observational study ancillary to JCOG1907 randomized controlled trial (JCOG1907A1).
- A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
- Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03).
- Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
- A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).
- A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
- Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer.
- A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.
- SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS ≥ 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE).
- Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
- Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease.
- Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
- INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
Presenter: Jiabin Zheng | Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
TPS415 Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.
Für Hintergrund und Methoden siehe Abstract
Presenter: Alice Guazzelli, PhD | University of Oxford
TPS416 Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.
Für Hintergrund und Methoden siehe Abstract
Presenter: Satoru Matsuda, MD, PhD | Department of Surgery, Keio University School of Medicine
TPS417 A randomized controlled phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced esophageal cancer with no pathological complete response: JCOG2206 (SUNRISE Trial).
Für Hintergrund und Methoden siehe Abstract
Presenter: Izuma Nakayama, MD, PhD | The Cancer Institute Hospital of the Japanese Foundation for Cancer Research
TPS418 Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
Für Hintergrund und Methoden siehe Abstract
Presenter: Ecaterina Elena Dumbrava, MD | Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
TPS419 First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.
Für Hintergrund und Methoden siehe Abstract
Presenter: Ronan Joseph Kelly, MD, MBA | Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas
TPS420 A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Susanna Varkey Ulahannan, MD | University of Okahoma Health Sciences Center
TPS421 Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.
Für Hintergrund und Methoden siehe Abstract
Presenter: Keiichi Fujiya, MD, PhD | Division of Gastric Surgery, Shizuoka Cancer Center
TPS422 Surgeon fatigue in robot-assisted and laparoscopic gastrectomy for gastric cancer: Exploratory prospective observational study ancillary to JCOG1907 randomized controlled trial (JCOG1907A1).
Für Hintergrund und Methoden siehe Abstract
Presenter: Hiroyuki Arai, MD, PhD | Department of Clinical Oncology, St. Marianna University School of Medicine
TPS423 A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
Für Hintergrund und Methoden siehe Abstract
Presenter: Yelena Y. Janjigian, MD | Memorial Sloan Kettering Cancer Center
TPS424 Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03).
Für Hintergrund und Methoden siehe Abstract
Presenter: Carlos Rojas, MD | Centro de Investigacion Clinica, Bradford Hill
TPS425 Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
Für Hintergrund und Methoden siehe Abstract
Presenter: Jian Xiao, Doctor of Medicine | Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences
TPS426 A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).
Für Hintergrund und Methoden siehe Abstract
Presenter: Lin Shen, MD, PhD | Department of GI Oncology, Peking University Cancer Hospital & Institute
TPS427 A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
Presenter: Han Liang | Tianjin Medical University Cancer Institute and Hospital
TPS428 Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer.
Für Hintergrund und Methoden siehe Abstract
Presenter: Meredith Pelster, MD, MSc | Sarah Cannon Research Institute, Tennessee Oncology
TPS429 A phase I study of EO-3021 in adult patients with solid tumors likely to express CLDN18.2.
Für Hintergrund und Methoden siehe Abstract
Presenter: Anwaar Saeed, MD | University of Pittsburgh Medical Center
TPS430 SWOG S2303: Randomized phase II/III trial of 2nd line nivolumab + paclitaxel + ramucirumab versus paclitaxel + ramucirumab in patients with PD-L1 CPS ≥ 1 advanced gastric and esophageal adenocarcinoma (PARAMUNE).
Für Hintergrund und Methoden siehe Abstract
Presenter: Thorsten Goetze, Prof. Dr. | Krankenhaus Nordwest, University Cancer Center Frankfurt
TPS431 Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
Für Hintergrund und Methoden siehe Abstract
Presenter: Reetu Mukherji, MD | Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University
TPS765 Evaluating novel therapies and circulating tumor DNA (ctDNA) as a marker of response in curatively treated gastrointestinal cancers with microscopic residual disease.
Für Hintergrund und Methoden siehe Abstract
Presenter: Michael C. Heinrich, MD, FACP | Oregon Health & Science University Knight Cancer Institute
TPS766 Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
Für Hintergrund und Methoden siehe Abstract
Presenter: Jiabin Zheng | Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
TPS767 INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations.
Für Hintergrund und Methoden siehe Abstract
Copyright 2024. All Rights Reserved.